Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2018: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2017: ¥10,010,000 (Direct Cost: ¥7,700,000、Indirect Cost: ¥2,310,000)
|
Outline of Final Research Achievements |
Our previous study has showed that TRPV1-positive afferents are involved in both cancer growth and cancer-induced pain. QX-314, a quaternary lidocaine derivative, has a permanent positive charge that theoretically impairs its ability to cross neuronal membranes. However, When TRPV1 was activated, extracellular QX-314 could produce a local anesthetic effect through entering the pore of TRPV1. Our results of this study revealed that systemic QX-314 decreases both cancer pain and cancer growth due to inhibition of activated TRPV1-positive afferents.
|